The weekly litigation news digest is live. Subscribe now

IP Verse

Administration Of Deuterated Cftr Potentiators - EP3352757

The patent EP3352757 was granted to Vertex Pharmaceuticals Europe on Aug 16, 2023. The application was filed on Sep 21, 2016 under application number EP16849524A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3352757

VERTEX PHARMACEUTICALS EUROPE
Application Number
EP16849524A
Filing Date
Sep 21, 2016
Status
Granted And Under Opposition
Jul 14, 2023
Publication Date
Aug 16, 2023
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
GENERICS UKMay 16, 2024TER MEER STEINMEISTER & PARTNERADMISSIBLE

Patent Citations (14) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS2006079502
DESCRIPTIONUS2006094744
DESCRIPTIONUS7014866
DESCRIPTIONUS8754224
DESCRIPTIONUS8865902
DESCRIPTIONUS8883206
INTERNATIONAL-SEARCH-REPORTUS2014073667
INTERNATIONAL-SEARCH-REPORTUS2014221424
OPPOSITIONUS2015099780
OPPOSITIONWO2010019239
OPPOSITIONWO2011146901
OPPOSITIONWO2017053455
SEARCHUS2011288122
SEARCHUS2015099780

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents